FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385852747> ?p ?o ?g. }

• W4385852747 abstract "Background Patients with leukemia relapse after allogeneic hematopoietic cell transplant (HCT) have poor survival due to toxicity and disease progression. A second HCT often offers the only curative treatment. Methods We retrospectively reviewed our bi-institutional experience (MSKCC-USA; Utrecht-NL) with unrelated cord blood transplantation (CBT) for treatment of post-transplant relapse. Overall survival (OS) and event-free survival (EFS) were evaluated using the Kaplan-Meier method, treatment-related mortality (TRM) and relapse were evaluated using the competing risk method by Fine-Gray. Results Twenty-six patients age &lt; 21 years received a second (n=24) or third (n=2) HCT with CB grafts during the period 2009-2021. Median age at first HCT (HCT1) was 11.5 (range: 0.9-17.7) years and all patients received myeloablative cytoreduction. Median time from HCT1 to relapse was 12.8 (range 5.5-189) months. At CBT, median patient age was 13.5 (range 1.4-19.1) years. Diagnoses were AML: 13; ALL: 4, MDS: 5, JMML: 2; CML: 1; mixed phenotype acute leukemia: 1. Sixteen patients (62%) were in advanced stage, either CR&gt;2 or with active disease. Median time from HCT1 to CBT was 22.2 (range 7-63.2) months. All patients engrafted after CBT. Thirteen patients developed acute GvHD; 7 had grade III or IV. With a median survivor follow-up of 46.6 (range 17.4-155) months, 3-year OS was 69.2% (95% CI 53.6-89.5%) and 3-year EFS was 64.9% (95% CI 48.8-86.4%). Eight patients died, 3 of AML relapse and 5 due to toxicity (respiratory failure [n=4], GvHD [n=1]) at a median time of 7.7 (range 5.9-14.4) months after CBT. Cumulative incidence of TRM at 3 years was 19.2% (95% CI 4.1-34.4%). Notably, all TRM events occurred in patients transplanted up to 2015; no toxicity-related deaths were seen in the 16 patients who received CBT after 2015. Cumulative incidence of relapse was 15.9% (95% CI 1.6-30.2%) at 3 years, remarkably low for these very high-risk patients. Conclusions Survival was very encouraging following CB transplants in pediatric patients with recurrent leukemia after first HCT, and TRM has been low over the last decade. CBT needs to be strongly considered as a relatively safe salvage therapy option for post-transplant relapse." @default.
• W4385852747 created "2023-08-17" @default.
• W4385852747 creator A5001390394 @default.
• W4385852747 creator A5012953935 @default.
• W4385852747 creator A5042013596 @default.
• W4385852747 creator A5052353546 @default.
• W4385852747 creator A5052956899 @default.
• W4385852747 creator A5055001531 @default.
• W4385852747 creator A5059824947 @default.
• W4385852747 creator A5067848684 @default.
• W4385852747 creator A5067921351 @default.
• W4385852747 creator A5074947199 @default.
• W4385852747 creator A5076653129 @default.
• W4385852747 creator A5079103223 @default.
• W4385852747 creator A5082616655 @default.
• W4385852747 creator A5085595407 @default.
• W4385852747 date "2023-08-15" @default.
• W4385852747 modified "2023-09-27" @default.
• W4385852747 title "Excellent leukemia control after second hematopoietic cell transplants with unrelated cord blood grafts for post-transplant relapse in pediatric patients" @default.
• W4385852747 cites W2183814412 @default.
• W4385852747 cites W2355957004 @default.
• W4385852747 cites W2394856879 @default.
• W4385852747 cites W2402799752 @default.
• W4385852747 cites W2413651842 @default.
• W4385852747 cites W2469920142 @default.
• W4385852747 cites W2514964903 @default.
• W4385852747 cites W2560686337 @default.
• W4385852747 cites W2592871544 @default.
• W4385852747 cites W2770403440 @default.
• W4385852747 cites W2889783565 @default.
• W4385852747 cites W2899440429 @default.
• W4385852747 cites W2901206201 @default.
• W4385852747 cites W2906119683 @default.
• W4385852747 cites W2912726542 @default.
• W4385852747 cites W2931381013 @default.
• W4385852747 cites W2967105092 @default.
• W4385852747 cites W3004179367 @default.
• W4385852747 cites W3032103006 @default.
• W4385852747 cites W3034304538 @default.
• W4385852747 cites W3044536206 @default.
• W4385852747 cites W3045923563 @default.
• W4385852747 cites W3111771166 @default.
• W4385852747 cites W3137855792 @default.
• W4385852747 cites W4307231340 @default.
• W4385852747 cites W4317037753 @default.
• W4385852747 doi "https://doi.org/10.3389/fonc.2023.1221782" @default.
• W4385852747 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37649924" @default.
• W4385852747 hasPublicationYear "2023" @default.
• W4385852747 type Work @default.
• W4385852747 citedByCount "0" @default.
• W4385852747 crossrefType "journal-article" @default.
• W4385852747 hasAuthorship W4385852747A5001390394 @default.
• W4385852747 hasAuthorship W4385852747A5012953935 @default.
• W4385852747 hasAuthorship W4385852747A5042013596 @default.
• W4385852747 hasAuthorship W4385852747A5052353546 @default.
• W4385852747 hasAuthorship W4385852747A5052956899 @default.
• W4385852747 hasAuthorship W4385852747A5055001531 @default.
• W4385852747 hasAuthorship W4385852747A5059824947 @default.
• W4385852747 hasAuthorship W4385852747A5067848684 @default.
• W4385852747 hasAuthorship W4385852747A5067921351 @default.
• W4385852747 hasAuthorship W4385852747A5074947199 @default.
• W4385852747 hasAuthorship W4385852747A5076653129 @default.
• W4385852747 hasAuthorship W4385852747A5079103223 @default.
• W4385852747 hasAuthorship W4385852747A5082616655 @default.
• W4385852747 hasAuthorship W4385852747A5085595407 @default.
• W4385852747 hasBestOaLocation W43858527471 @default.
• W4385852747 hasConcept C126322002 @default.
• W4385852747 hasConcept C141071460 @default.
• W4385852747 hasConcept C2776694085 @default.
• W4385852747 hasConcept C2777408962 @default.
• W4385852747 hasConcept C2778461978 @default.
• W4385852747 hasConcept C2779709957 @default.
• W4385852747 hasConcept C2780914630 @default.
• W4385852747 hasConcept C2911091166 @default.
• W4385852747 hasConcept C71924100 @default.
• W4385852747 hasConcept C90924648 @default.
• W4385852747 hasConceptScore W4385852747C126322002 @default.
• W4385852747 hasConceptScore W4385852747C141071460 @default.
• W4385852747 hasConceptScore W4385852747C2776694085 @default.
• W4385852747 hasConceptScore W4385852747C2777408962 @default.
• W4385852747 hasConceptScore W4385852747C2778461978 @default.
• W4385852747 hasConceptScore W4385852747C2779709957 @default.
• W4385852747 hasConceptScore W4385852747C2780914630 @default.
• W4385852747 hasConceptScore W4385852747C2911091166 @default.
• W4385852747 hasConceptScore W4385852747C71924100 @default.
• W4385852747 hasConceptScore W4385852747C90924648 @default.
• W4385852747 hasLocation W43858527471 @default.
• W4385852747 hasLocation W43858527472 @default.
• W4385852747 hasOpenAccess W4385852747 @default.
• W4385852747 hasPrimaryLocation W43858527471 @default.
• W4385852747 hasRelatedWork W2003938723 @default.
• W4385852747 hasRelatedWork W2047967234 @default.
• W4385852747 hasRelatedWork W2118496982 @default.
• W4385852747 hasRelatedWork W2364998975 @default.
• W4385852747 hasRelatedWork W2366793411 @default.
• W4385852747 hasRelatedWork W2369162477 @default.
• W4385852747 hasRelatedWork W2439875401 @default.
• W4385852747 hasRelatedWork W2991049463 @default.
• W4385852747 hasRelatedWork W4238867864 @default.
• W4385852747 hasRelatedWork W2525756941 @default.

• next